|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/33 | (2006.01) |
| A61P 1/16 | (2006.01) |
| (11) | Number of the document | 3129018 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15728222.9 |
| Date of filing the European patent application | 2015-04-10 | |
| (97) | Date of publication of the European application | 2017-02-15 |
| (45) | Date of publication and mention of the grant of the patent | 2019-10-23 |
| (46) | Date of publication of the claims translation | 2020-01-10 |
| (86) | Number | PCT/US2015/025416 |
| Date | 2015-04-10 |
| (87) | Number | WO 2015/157697 |
| Date | 2015-10-15 |
| (30) | Number | Date | Country code |
| 201461978335 P | 2014-04-11 | US |
| (72) |
ROBERTS, Brian, US
WANG, Xueyan, US
CHOI, Yun-Jung, US
KARPF, David, US
MARTIN, Robert, US
MCWHERTER, Charles A., US
|
| (73) |
CymaBay Therapeutics, Inc.,
7575 Gateway Boulevard, Suite 110, Newark, CA 94560,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | NAFLD ir NASH gydymas |
| TREATMENT OF NAFLD AND NASH |
| Payment date | Validity (years) | Amount | |
| 2026-03-03 | 12 | 289.00 EUR |
| 2027-04-10 |